The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.

MLA

Yang, Yingzhu, et al. “The Efficacy and Safety of the Addition of Poly ADP-Ribose Polymerase (PARP) Inhibitors to Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.” World Journal of Surgical Oncology, vol. 18, no. 1, July 2020, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12957-020-01931-7.

APA

Yang, Y., Du, N., Xie, L., Jiang, J., Mo, J., Hong, J., Mao, D., Ng, D. M., & Shi, H. (2020). The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 18(1), 1–11. https://doi.org/10.1186/s12957-020-01931-7

Chicago

Yang, Yingzhu, Nannan Du, Laidi Xie, Jing Jiang, Jiahang Mo, Jiaze Hong, Danyi Mao, Derry Minyao Ng, and Huiwei Shi. 2020. “The Efficacy and Safety of the Addition of Poly ADP-Ribose Polymerase (PARP) Inhibitors to Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.” World Journal of Surgical Oncology 18 (1): 1–11. doi:10.1186/s12957-020-01931-7.